ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
MRI features outperform histologic grade for outcome prediction in translocation-driven enriched soft-tissue sarcoma.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMost MR-based prognostic series in soft-tissue sarcoma (STS) were derived in cohorts dominated by complex-karyotype histologies; whether conventional MR descriptors retain prognostic value in translocation-driven enriched populations is unclear. The purpose of our study is to identify preoperative MR features independently associated with overall survival (OS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS) in a translocation-driven enriched soft-tissue sarcoma cohort.
methodsIn this retrospective single-center study, consecutive adults with histologically confirmed STS who underwent contrast-enhanced MRI before treatment between January 2008 and December 2024 were evaluated. Two radiologists blinded to outcome independently scored 13 prespecified MR features. Cox regression adjusted for age, sex, maximum tumor diameter, and Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade was used to estimate hazard ratios (HRs); a sensitivity analysis added translocation-driven histology.
resultsA total of 158 patients (mean age, 48 years ± 19 [SD]; 84 men) were evaluated; 61 of 152 classifiable patients (40%) had translocation-driven tumors. After adjustment for age, sex, and maximum tumor diameter, heterogeneous gadolinium enhancement was independently associated with shorter OS (HR, 3.9 [95% CI: 1.4, 10.7]; P = .008). Peritumoral edema was independently associated with shorter OS (HR, 2.0 [95% CI: 1.0, 3.7]; P = .04) and was the single independent MR predictor of LRFS (HR, 2.3 [95% CI: 1.2, 4.5]; P = .01). Both associations persisted after adjustment for translocation-driven histology. A 13-feature MR panel did not discriminate FNCLCC grade 3 (area under the curve [AUC], 0.59).
conclusionPeritumoral edema and heterogeneous gadolinium enhancement were independent, complementary MR predictors of outcome in translocation-driven enriched soft-tissue sarcoma, outperforming FNCLCC grade and molecular histologic class. These findings require prospective multicenter validation before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.